MicroPort® Awarded with National-Level “Quality Benchmark” Award for second consecutive year

Taiyuan, China, 30 October, 2020 - On October 21st, 2020, Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®) was announced as a winner of the national-level “Quality Benchmark” company award at the National Quality Benchmarking Shanxi Exchange Activity, held in Taiyuan, Shanxi Province. The award, received for the second year in a row, was awarded to MicroPort® for its “practical experience in implementing comprehensive product risk management and control.”

National-level “Quality Benchmark” is a selection activity led by China Association for Quality in answer to both the Implementation Opinions of the Ministry of Industry and Information Technology on Promoting Improvement of the Quality of Products and Services in the Manufacturing Industry and the requirements put forward in the Ministry’s Notice on Building Quality Industrial Brands in 2020. Winners of the award have gone through the process of application, preliminary eligibility check, presentation and defense, expert panel review, and results validation. This activity aims at promoting advanced quality management methods, strengthening brand building through quality improvement, and achieving quality development of industries.

MicroPort® applied for this award due to its practical experience in implementing comprehensive product risk management and control, which is based on a risk management system established through years of practice in line with leading international regulatory requirements. MicroPort® has summarized the system as a combination of core elements “1+2+3+4” for risk management and control. That is, under 1 fundamental concept centering around product safety and effectiveness, 2 cyclic missions of product life cycle and operational risk control are carried out in parallel across 3 most important stages in product life cycle, namely design and development, manufacturing, and post-launch management, and overall product risk management follows 4 steps of risk identification, risk evaluation, risk control, and residual risk acceptability assessment. This management system at MicroPort® won unanimous applause from the judging panel because it is not only scientific, innovative, and methodical, but also exemplary, effective, and full of development potential.

Since its birth in 1998, MicroPort® has always put “quality” above the rest of its eight corporate values, building itself as a brand truly acting for the needs of patients and doctors. In recent years, MicroPort® has been awarded the Golden Quality Award of Shanghai Municipality, certified as a “Shanghai Brand” among the earliest winners of this recognition, and chosen as a “Quality Benchmark” in Shanghai for consecutive years. The national-level “Quality Benchmark” recognition this time is a strong testimony of the long-standing quality of MicroPort® when it comes to products and corporate management. In the future, MicroPort® is committed to continuously giving full play to the roles of quality and innovation in its development, providing more integrated and inclusive medical solutions to save or improve patients’ lives, and contributing to high-quality development of the whole industry.